Comparison of serum from lung cancer patients and from patients with benign lung nodule using FTIR spectroscopy

Lung cancer remains the leading cause of cancer related deaths in worldwide. Early diagnosis of lung cancer can significantly improve survival rate. However, due to its close resemblance to the malignant nodules, the possible existence of benign nodules often leads to erroneous decisions. The aim of this study was to explore whether fourier transform infrared (FTIR) spectroscopy could improve the accuracy of early diagnosis of lung cancer by distinguishing lung cancer patients' (LCP') serum from patients with benign lung nodules' (PBLN') serum. In this study, A1243+1081/A1652+1539 ratio in LCP group was increased significantly compared with that in PBLN group, indicating that the ratio could be used to distinguish the serum of LCP from that of PBLN. In addition, the ratios of A2926/A2969, A1744/A2926+2859, A2926+2859/A1652+1539 were also increased significantly in LCP group compared with that in PBLN group. These findings suggest that FTIR spectroscopy might be a potentially effective method for the early diagnosis of lung cancer.

Automated summary

This study used Fourier Transform Infrared (FTIR) spectroscopy to explore the accuracy of early diagnosis of lung cancer. The results showed that by distinguishing specific ratios in patients' serum, lung cancer patients can be effectively differentiated from patients with benign nodules.